Skip to main content
. Author manuscript; available in PMC: 2014 Dec 30.
Published in final edited form as: Bone Marrow Transplant. 2013 Jun 17;48(11):1437–1443. doi: 10.1038/bmt.2013.79

Figure 2.

Figure 2

BM disease burden. BM disease burden is reduced after clofarabine. (a) The median BM blast percentage was 22% (mean = 30%, range 0–86%) before clofarabine and 5% (mean = 18%, range 0–75%) after clofarabine (P = 0.035). (b) The median BM cellularity was 41% (mean = 31%, range 5–100%) before clofarabine and 10% (mean = 17%, range 1–75%) after clofarabine (P < 0.0001). (c) Post clofarabine nadir BM cellularity and blasts by disease category. Each column represents a single patient’s result.